AdolescentsTreatment-Resistant Depression (TRD)Depressive DisordersPTSDAnxiety DisordersSuicidality

Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics

This observational survey study (n=1,967) assessed the prevalence and perceived efficacy of self-medicating with psychedelics among users with mental health conditions. It finds that while self-medication was not universal, those who used psychedelics for this purpose reported significantly higher symptom reduction and quality of life improvements compared with conventional medical treatments.

Authors

  • Kim Kuypers
  • Nathalie Mason

Published

Journal of Psychedelic Studies
individual Study

Abstract

Background

A substantial number of people worldwide suffer from mental health problems during their lifetime. First-line treatments are not effective for everybody. Recent studies suggest that psychedelic drugs have high therapeutic potential for a variety of mental disorders.

Aims

This survey study aimed to assess the tendency of psychedelic users to self-medicate with psychedelics and to compare the effectiveness of self-administered psychedelics to treat their disorder and the treatment offered by a medical professional.Methods and results: In total, 1,967 respondents consented were ≥18 years and completed the questionnaire. The mean (±SD) age was 25.9 (8.7); 79% were males, 20% females, and 1% classified themselves as “other.” Almost half of the respondents (46%) indicated to have suffered/to be suffering from a mental disorder, with 77% being diagnosed by a medical professional. In 99% of the diagnosed cases, the treatment was offered; 77% searched for treatments outside a medical professional’s recommendation with 81% who had used/were using psychedelics to treat/cure symptoms. Self-administered psychedelic treatment had a higher likelihood of being efficacious, with higher symptoms reduction and larger quality of life improvement compared to treatment offered by a medical professional.

Conclusions

Lifetime prevalence of psychopathologies in the current sample of psychedelic drug users seemed to be higher than in the general population. Self-medication with psychedelics was not highly frequent; although when it occurred, it was rated as significantly more effective as treatment offered by a medical professional. Current findings support research exploring the potential of psychedelics in the treatment of psychopathologies.

Available with Blossom Pro

Research Summary of 'Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics'

Introduction

Mason and colleagues situate the study within renewed scientific interest in classical psychedelics (for example, psilocybin, LSD, ayahuasca) and related entactogens (MDMA) as potential treatments for a range of psychiatric conditions, including treatment‑resistant depression, PTSD and substance-use disorders. They note that although standard therapies (psychotherapy, antidepressants, anxiolytics) benefit many patients, a substantial minority remain symptomatic, motivating exploration of novel therapeutic agents. Population surveys have reported that lifetime use of psychedelics is not consistently associated with worse mental health and in some large samples has been linked to lower odds of psychological distress and suicidality. This background raises the question whether people who have used psychedelics attempt to self‑medicate psychiatric or physical illness with these substances. The present study therefore aimed to estimate the prevalence of self‑reported psychiatric disorders in a self‑selected sample of psychedelic users and to assess whether those with diagnosed disorders sought treatments outside conventional medical advice, specifically whether they used psychedelics to treat symptoms. The investigators also compared self‑rated effectiveness of standard treatments offered by medical professionals with self‑administered psychedelic treatments, and hypothesised that psychedelic users with a diagnosed psychopathology would be likely to self‑medicate with psychedelics.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (21)

Papers cited by this study that are also in Blossom

Health status of ayahuasca users

Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Show all 21 references
Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Experiences of Encounters with Ayahuasca - “the Vine of the Soul”

Kjellgren, A., Eriksson, A., Norlander, T. · Journal of Psychoactive Drugs (2009)

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry

Sessa, B. · Journal of Psychoactive Drugs (2014)

Blockade of 5-HT 2 receptor selectively prevents MDMA-induced verbal memory impairment

Kuypers, K. P. C., Theunissen, E. L., Bosker, W. M. et al. · Neuropsychopharmacology (2011)

45 cited

Cited By (8)

Papers in Blossom that reference this study

Effects of psychedelics in older adults: A prospective cohort study

Kettner, H., Roseman, L., Gazzaley, A. et al. · The American Journal of Geriatric Psychiatry (2024)

12 cited
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)

The challenges ahead for psychedelic ‘medicine’

Muthukumaraswamy, S., Forsyth, A., Sumner, R. L. · Australian and new-zealand Journal of Psychiatry (2022)

65 cited
Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

95 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.